DIAGNOSTIC SIGNIFICANCE OF THE HE-4 TUMOR MARKER IN THE STAGING OF OVARIAN CANCER
Introduction. Ovarian cancer is not a rare pathology and accounts for 4–6 % of all malignant neoplasms in the female population. Diagnostics of ovarian cancer at an early stage is a key approach to improving the effectiveness of treatment for this pathology. The use of sensitive serological tumor-associated markers is considered an adequate approach for diagnosis, monitoring of treatment efficacy and preclinical detection of recurrence for tumors of a number of localizations, in particular ovarian cancer.
The objective. To evaluate the diagnostic significance of the HE-4 tumor marker in comparison with the CA-125 tumor marker depending on the stage of malignant tumors of the ovaries (MTO).
Methods. The paper is based on the authors’ own clinical observations of 245 patients for the 2015 to 2017 period in SI “Grigoriev Institute for Medical Radiology of National Academy of Medical Sciences of Ukraine». The article presents the results of the study of the HE-4 and CA-125 tumor markers levels in 181 patients with I–IV stage (basic group) of MTO and in 64 women with benign ovarian neoplasms (control group). The criterion for inclusion in the study was an exclusively voluntary informed consent of the patient; exclusion from the study was carried out in the event of the patient's refusal to continue to participate in the study at any stage or if the specific clinical case was not corresponding to the purpose and objectives of the study. In the course of the study clinical, biochemical, immunoenzymatic and radiological methods of examination were used. Statistical processing of the data was carried out using the «STATISTICA 10.0» software package.
Results. The mean levels of expression of the HE-4 tumor-associated marker are consistently increasing in accordance with the spread of the process, differing significantly in-between them when comparing the early and late stages of MTO. The incidence of HE-4-positive cases is quite high regardless of the stage of the process. Sensitivity of the HE-4 tumor-associated marker irrespective of the disease stage was 92.82 %, CA-125 – 89.50 %, however, the specificity of the HE-4 marker significantly exceeds the specificity of CA-125 and is 95.31 and 60.92 % respectively. The sensitivity of the HE-4 protease inhibitor is significantly higher than that of CA-125 in the early stages of the development of the malignant process (stage I–II) and practically does not differ in the neglected stages of malignant tumors of the ovaries. The analysis of auxiliary informative criteria has shown the probable advantage of the HE-4 tumor marker in comparison with CA-125 in all parameters, except for the incidence of false negative results.
Conclusions. It was discovered that the HE-4 tumor marker is stage dependent. It has been established that the specificity of the protease inhibitor HE-4 exceeds the specificity of the oncofetal protein CA-125 by 1,5 times, which allows recommending its use in the diagnosis of malignant tumors of the ovaries.
Key words: malignant tumors of the ovaries; tumor-associated markers; HE-4; CA-125; diagnostic significance.
Kateryna V. Nemaltsova,
Olena M. Sukhina,
Vladyslav S. Sukhin
SI “Grigoriev Institute for Medical Radiology of National Academy of Medical Sciences of Ukraine»,
Kharkov, Ukraine
References:
1. Aksel' E.M. Statistika zlokachestvennykh novoobrazovaniy zhenskoy polovoy sfery [Statistics of malignant neoplasms of the female sexual sphere]. Onkoginekologiya [Oncogynecology]. 2012. № 1. pp.18–24. [in Russian]
2. Antoshechkina M.A., Savinova E.B. Ispol'zovanie biomarkerov dlya ranney diagnostiki raka yaichnikov [Using biomarkers for early diagnosis of ovarian cancer]. Klinicheskiy vestnik [Clinical Herald]. 2011. № 4. pp.91–93. [in Russian]
3. Akhmedova S.A. Sovershenstvovanie kliniko-laboratornoy kontseptsii ispol'zovaniya СA 125 u bol'nykh rakom yaichnikov (doct. diss.) [Improvement of clinical and laboratory concept of CA 125 use in patients with ovarian cancer. Doct. Diss.]. Moscow, 2003. 130 p. [in Russian]
4. Vasil'ev A.N., Krasil'nikov S.E., Voitsitskii V.E., Gerasimov A.V., Kulidzhanyan A.P., Babayats E.V., Sisakjan V.G., Krylyshkin M.I., Afanas'eva N.A., Mansurova A.S. Onkomarkery CA125, HE4 kak prediktornye faktory prognoza u bol'nykh s pogranichnymi opukholyami yaichnikov [Oncomarkers CA125, HE4 as predictors of prognosis in patients with borderline ovarian tumors]. Sib. onkol. zhurn [Siberian oncol. J.]. 2015. №4. P. 39–44. [in Russian]
5. Zhordania K.I. Nekotorye aspekty diagnostiki i lecheniya raka yaichnikov [Some aspects of diagnosis and treatment of ovarian cancer]. Rus. med. zhurn. [Russian medical journal]. 2002. №24. pp. 1095–1102. [in Russian]
6. Zhordania K.I., Gershteyn E.S., Kushlinskiy N.E. Kozachenko V.P., Blyumenberg A.G., Nikogosyan S.O., Gubina G.I. Opukholi yaichnikov [Ovarian tumors]. Klinicheskaya onkoginekologiya [Clinical oncogynelogy]. Pod red. [edited by] V.P. Kozachenko. M.: Meditsina [Medicine]. 2005. pp. 220–269. [in Russian]
7. Lektsii po klinicheskoy onkologii [Lectures on clinical oncology] / Pod red. [edited by] prof. G.V. Bondar. Lugansk, 2009. 578 p. [in Russian]
8. Marshutina N.V., Solokhina M.P., Alentov I.I., Sergeeva N.S. Klinicheskaya znachimost' biologicheskikh markerov pri rake yaichnikov, rake predstatel'noy zhelezy, kolorektal'nom rake [Clinical significance of biological markers for ovarian cancer, prostate cancer, colorectal cancer]. Issledovaniya i praktika v meditsine [Research and practice in medicine]. 2016. T.3. №1. pp.46–57. [in Russian]
9. Rak v Ukraїnі, 2015–2016. Zakhvoryuvanіst', smertnіst', pokazniki dіyal'nostі onkologіchnoї sluzhbi [Cancer in Ukraine, 2015-2016. Incidence, mortality, activities of oncological service]. Byuleten' Natsіonal'nogo kantser-reєstru Ukraїni № 18 [Bulletin of National Cancer Registry of Ukraine]. K., 2017. pp.52–53. [in Ukrainian]
10. Severskaya N.V., Chebotareva I.V., Sychenkova N.I., Dvinskih N.U., Krikunova L.I. Opukholevye markery SA125, NE4 i ROMA v differentsial'noi diagnostike raka yaichnika u zhenshhin v pre- i postmenopauze [Tumor markers CA125, HE4 and ROMA in differential diagnostics of ovarian cancer in pre- and postmenopausal women]. Onkologiya reproduktivnykh organov: ot profilaktiki i rannego vyyavleniya k effektivnomu lecheniyu: mater. I Natsional'nogo kongressa, 19–21 maya 2016 [Oncology of reproductive organs: from prevention and early detection to effective treatment: materials of the I National Congress, May 19–21, 2016]. Moscow, 2016. P. 143. [in Russian]
11. Sergeeva N.S., Marshutina N.V. Opukholeassotsiirovannye markery v skriningovykh programmakh, napravlennykh na aktivnoe vyyavlenie raka yaichnikov: real'nost', problemy i perspektivy [Tumor-associated markers in screening programs aimed at active detection of ovarian cancer: reality, problems and prospects]. Prakticheskaya onkologiya. Problemy skrininga v onkologii [Practical oncology. Problems of screening in oncology]. 2010. №11 (2). pp.110–119. [in Russian]
12. Sergeeva N.S., Marshutina N.V. Serologicheskie opukholeassotsiirovannye markery: natsional'noe rukovodstvo [Serological tumor-associated markers: national guidelines]. Onkologiya [Oncology]. Pod red. [edited by] V.I. Chissov, M.I. Davydov. M.: GEOTAR-Media, 2008. pp.8–26. [in Russian]
13. Chernobay A.V. Rak yaichnika: patogenez, diagnostika, sovremennye aspekty lecheniya [Ovarian cancer: pathogenesis, diagnosis, modern aspects of treatment]. Vestnik problem biologii i meditsiny [Bulletin of problems in biology and medicine]. 2013. Vyp. 2. pp. 33–38. [in Russian]
14. Anastasi E., Granato T., Falzarano R., Storelli P., Ticino A., Frati L., Panici P.B., Porpora M.G. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J. Ovar. Res. 2013. Vol.6. №44. Р. 2–8.
15. Bolstad N., Øijordsbakken M., Nustad K., Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012. Vol. 33. № 1. Р. 141–148.
16. Escudero J. M., Auge J. M., Filella X., Torne A., Pahisa J., Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin. Chem. 2011. Vol. 57. № 11. Р. 1534–1544.
17. Galgano M.T., Hampton G.M., Frierson H.F.Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006. Vol. 19. № 6. Р. 847–853.
18. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod. 1991. Vol. 45. № 2. Р. 350–357.
19. Moоre D.H. Primary surgical management of early epithelial ovarian carcinoma. Ovarian cancer. 2001. P. 201–218..
20. Menczer J., Usviatzov I., Ben-Shem E., Golan A., Levy T. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J. Gynecol. Oncol. 2011. Vol. 22. № 3. P. 183–187.
21. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011. Vol. 61. № 4. P. 212–236.
22. Sölétormos G., Duffy M.J., Othman Abu Hassan S., Verheijen R.H., Tholander B., Bast R.C., Gaarenstroom K.N., Sturgeon C.M., Bonfrer J.M., Petersen P.H., Troonen H., CarloTorre G., Kanty Kulpa J., Tuxen M.K., Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int. J. Gynecol. Cancer. 2016. Vol. 26. № 1. Р. 43–51.
23. Weinberg L.E., Rodriguez G., Hurteau J.A. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J. Surg. Oncol. 2010. Vol.101. №4. P. 334–343.
Bibliography link
Nemaltsova K.V., Sukhina Ye.M., Sukhin V.S. Diagnostic significance of the HE-4 tumor marker in the staging of ovarian cancer. Nauka i Zdravookhranenie [Science & Healthcare]. 2017, 6, pp. 28-42.